E-resources
Peer reviewed
Open access
-
Nakamura, Yoshiaki; Yamashita, Riu; Okamoto, Wataru; Komatsu, Yoshito; Yuki, Satoshi; Ueno, Makoto; Kato, Ken; Taniguchi, Hiroya; Kagawa, Yoshinori; Denda, Tadamichi; Hara, Hiroki; Esaki, Taito; Moriwaki, Toshikazu; Sunakawa, Yu; Oki, Eiji; Nagashima, Fumio; Nishina, Tomohiro; Satoh, Taroh; Kawakami, Hisato; Yamaguchi, Kensei; Ohtsubo, Koushiro; Kato, Takeshi; Horita, Yosuke; Tsuji, Akihito; Yasui, Hisateru; Goto, Masahiro; Hamamoto, Yasuo; Wakabayashi, Masashi; Ikeno, Takashi; Shitara, Kohei; Bando, Hideaki; Tsuchihara, Katsuya; Miki, Izumi; Ichiki, Hiroko; Ohtsu, Atsushi; Yoshino, Takayuki
JCO precision oncology, 03/2023, Volume: 7Journal Article
Genomic profiling programs have been implemented to apply next-generation sequencing (NGS) for facilitating trial enrollment. SCRUM-Japan GI-SCREEN is a large-scale genomic profiling program in advanced gastrointestinal cancers using a validated genomic assay with the goal of facilitating enrollment in targeted clinical trials, generating real-world data, and performing clinicogenomic analysis for biomarker discovery. Genotyping of tumor tissue samples from 5,743 patients with advanced gastrointestinal cancers enrolled in GI-SCREEN was centrally performed with NGS. Patients were enrolled in matched trials of targeted agents affiliated with GI-SCREEN on the basis of genotyping results. A total of 11 gastrointestinal cancers were included, with colorectal cancer being the most common. The median age ranged from 59 to 70.5 years across cancer types. Patients enrolled after initiation of first-line treatment had significantly longer overall survival (OS) than that before treatment initiation with a median survival time difference of 8.9 months and a hazard ratio (HR) ranging from 0.25 to 0.73 across cancer types, demonstrating an immortal time bias. One hundred and forty-nine patients received matched therapies in clinical trials on the basis of their identified alterations. Among patients with colorectal cancer harboring actionable alterations, the median OS was significantly longer in patients who received matched therapies in trials than in those who did not (HR, 0.52; 95% CI, 0.26 to 1.01; = .049). Cancer-specific pathway alterations were significantly associated with shorter survival and related to primary resistance to matched trial therapies. Our genomic profiling program led to patient enrollment in targeted clinical trials and improved survival of patients with colorectal cancer who received matched therapies in clinical trials. To avoid immortal time bias, precautions are needed when using data from patients who have undergone NGS testing after initiation of the evaluated treatment line.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.